Price
Frequently asked questions
What is Catalent's market capitalization?
What is the Earnings Per Share (EPS) for Catalent?
What are the analyst ratings and target price for Catalent's stock?
What is Catalent's revenue over the trailing twelve months?
What is the EBITDA for Catalent?
What is the free cash flow of Catalent?
What is the 5-year beta of Catalent's stock?
How many employees does Catalent have, and what sector and industry does it belong to?
What is the free float of Catalent's shares?
Financials
Market Cap
$10.79B5Y beta
1.14EPS (TTM)
-$2.269Free Float
178.50MRevenue (TTM)
$4.42BEBITDA (TTM)
$658.00MFree Cashflow (TTM)
$99.00MPricing
Analyst Ratings
The price target is $57.89 and the stock is covered by 9 analysts.
Buy
1
Hold
7
Sell
1
Information
Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides formulation, development, and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for oral solid doses forms, softgels, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms. It also provides formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.
16,900
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker